With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s manufacturing facility in Coppell, Texas, which is the company’s lone site in the world that produces Lokelma.
AstraZeneca to spend $445M to boost production of Lokelma at Texas plant
Latest from Blog
NNB Nutrition Showcased Next-Generation Sweeteners, Naturally Occurring Dipeptides, Ultra-Pure Creatine and Fermented Actives at SupplySide Global 2026
/PRNewswire/ — NNB Nutrition, the ingredient company behind the tagline “Pure. Potent. Precise Ingredients,” showcased its latest innovations at SupplySide… Post Views: 0
Multivitamin for Women Market Forecast to 2035, Driven by Personalized Nutrition Demand
The multivitamin for women market is set to expand through 2035, supported by rising demand for personalized nutrition and life-stage-specific formulations. Post Views: 0
The Research Hehind ApplePhenon
Post Views: 0
Cultivated wagyu beef gains UK pet food approval
Ivy Farm Technologies can now supply its cultivated wagyu beef to U.K. pet food brands, with its first commercial-scale production run expected to be completed in early 2027. Post Views: 0
Amino Acid Premixes Market Forecast to 2035: Demand Accelerates on Precision Livestock Feeding and Human Nutrition
The global amino acid premixes market is set to expand through 2035, driven by precision livestock feeding and rising demand for tailored human nutrition solutions. Post Views: 0